Manuela Georgescu
Psychiatry · Coral Gables, FLNPI 1912157306
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,503 of the $6,914 with a category attached, or 79.6%. It is spread thinly across 16 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,170 and has fallen 96.2% since, to $119 in 2024.
Across 296 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$734
- Otsuka America Pharmaceutical, Inc.$729
- Sunovion Pharmaceuticals Inc.$685
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$319
- plus $2K from 10 others
What the payments were for
- Consulting fees$1,40420%
- Food & beverage$5,50380%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,404 |
| AbbVie(2 entities) | 74 | $1,302 |
| Teva Pharmaceuticals USA, Inc. | 49 | $734 |
| Otsuka America Pharmaceutical, Inc. | 23 | $729 |
| Sunovion Pharmaceuticals Inc. | 51 | $685 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $319 |
| Neurocrine Biosciences, Inc. | 16 | $305 |
| Johnson & Johnson | 14 | $267 |
| Alkermes, Inc. | 13 | $260 |
| Vanda Pharmaceuticals Inc. | 10 | $239 |
| Lundbeck LLC | 11 | $215 |
| Indivior Inc. | 9 | $196 |
| Almatica Pharma LLC | 8 | $175 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Tris Pharma Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$1,636
- VRAYLAR$249
- AUSTEDO$125
- LATUDA$121
- ABILIFY MAINTENA$119
- ABILIFY ASIMTUFII$119
- Austedo XR$115
How this compares
$6,914 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluoxetine Hcl | 11 | $19 |
| Clonazepam | 13 | $19 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Coral Gables
- Ilan MelnickCoral Gables$2.8M
- Moraima TrujilloCoral Gables$121K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.